Shares of Poolbeg Pharma PLC (LON:POLB – Get Free Report) reached a new 52-week low on Tuesday . The company traded as low as GBX 2.70 ($0.03) and last traded at GBX 2.70 ($0.03), with a volume of 1791365 shares traded. The stock had previously closed at GBX 2.90 ($0.04).
Analyst Ratings Changes
Separately, Shore Capital reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, January 2nd.
View Our Latest Report on POLB
Poolbeg Pharma Stock Up 0.4 %
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Further Reading
- Five stocks we like better than Poolbeg Pharma
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Undervalued Stocks You Can Buy at a Discount Now
- 3 REITs to Buy and Hold for the Long Term
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Where Do I Find 52-Week Highs and Lows?
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
